EVERIST GENOMICS INC has a total of 31 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2012. It filed its patents most often in Australia, Canada and China. Its main competitors in its focus markets medical technology, computer technology and environmental technology are FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIVERSITY, GERRESHEIMER WILDEN GMBH and Perminova Inc.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 3 | |
#2 | Canada | 3 | |
#3 | China | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Israel | 3 | |
#6 | Republic of Korea | 3 | |
#7 | Mexico | 3 | |
#8 | United States | 3 | |
#9 | WIPO (World Intellectual Property Organization) | 3 | |
#10 | Brazil | 2 | |
#11 | Hong Kong | 1 | |
#12 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Medical technology | |
#2 | Computer technology | |
#3 | Environmental technology | |
#4 | Biotechnology |
# | Name | Total Patents |
---|---|---|
#1 | Lenehan Peter F | 16 |
#2 | Everist Thomas Stephen Iii | 9 |
#3 | Fry David W | 7 |
#4 | Worzel William P | 7 |
#5 | Almal Arpit | 7 |
#6 | Lehehan Peter F | 6 |
#7 | Everist Iii Thomas Stephen | 5 |
#8 | Thomas Stephen Everist Iii | 4 |
#9 | Peter F Lenehan | 4 |
#10 | Everist Thomas Stephen Iii Ts | 1 |
Publication | Filing date | Title |
---|---|---|
EP3316766A1 | System and method of assessing endothelial function | |
BR112015023253A2 | flow-mediated dilation to determine vascular age. | |
WO2012099872A1 | Prognostic signature for colorectal cancer recurrence |